Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Commentary|Articles|August 25, 2026
Behind the FDA Approval: “Historic” Iberdomide Trial Spotlights MRD End Point and Potential of CELMoDs Across Myeloma
Author(s)Surbhi Sidana, MD, Jonah Feldman
Fact checked by: Sabrina Serani, Cheney Gazzam Baltz
In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.
Advertisement
Advertisement
The
Related to this article
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Advertisement
Advertisement